Lapisteride

Lapisteride
Systematic (IUPAC) name
N-[1-(4-methoxyphenyl)-1-methylethyl]-3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide
Clinical data
  • Non-regulated
Oral[1]
Identifiers
142139-60-4 Yes
None
PubChem CID 9847295
ChemSpider 8023009 Yes
UNII T50SJ23G82 Yes
Chemical data
Formula C29H40N2O3
464.6395 g/mol
 Yes (what is this?)  (verify)

Lapisteride (INN; CS-891) is a dual inhibitor of both isoforms of the enzyme 5α-reductase.[2] It was under investigation for the treatment of benign prostatic hyperplasia (BPH) and androgenic alopecia,[2][3] but was never marketed.

See also

References

  1. ↑ Yada S, Ohya M, Ohuchi Y et al. (April 2003). "Solid phase transition of CS-891 enantiotropes during grinding". International Journal of Pharmaceutics 255 (1-2): 69–79. doi:10.1016/S0378-5173(03)00084-X. PMID 12672603.
  2. ↑ 2.0 2.1 Niiyama S, Kojima K, Hamada T, Happle R, Hoffmann R (December 2000). "The novel drug CS-891 inhibits 5alpha-reductase activity in freshly isolated dermal papilla of human hair follicles". European Journal of Dermatology 10 (8): 593–5. PMID 11125319.
  3. ↑ Bernan; British Pharmacopoeia Commission (February 2002). British Approved Names 2002. The Stationery Office. p. 157. ISBN 978-0-11-322558-3. Retrieved 17 November 2011.